Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Drug For Rare Disease Without Clinical Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Orphan Europe's Carbaglu approval was based on a retrospective analysis of case studies - but FDA has said it should not be viewed as a precedent.

You may also be interested in...



Japan Issues Development List For Unapproved Indications; Kyowa Hakko, BMS And Sanofi Lead Requests

MHLW solicited requests from medical associations for compounds with unapproved indications in Japan that would meet unmet medical needs.

Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says

Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.

Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says

Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.

Related Content

Topics

UsernamePublicRestriction

Register

PS070373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel